Getting your first neurotech customers is one challenge. Scaling to 50, then 500, then 5,000 is a different problem. We build growth strategies that account for regulatory constraints, long sales cycles, and the dynamics of selling brain science to enterprise buyers.

The Problem

Your early traction isn't translating into predictable growth

You've closed a handful of deals, maybe through founder-led sales or conference connections. But the pipeline is inconsistent, the sales cycle varies wildly from deal to deal, and you can't forecast revenue with any confidence. This is the most dangerous stage for a neurotech company — you have just enough traction to raise more capital, but not enough process to deploy that capital efficiently. Without a growth strategy, you'll scale your burn rate without scaling your revenue.

You're growing headcount faster than revenue

The natural instinct after a funding round is to hire — more engineers, more salespeople, more marketing. But in neurotech, adding headcount without the right commercial infrastructure means you're adding cost without proportional revenue. Your sales team doesn't have a repeatable process. Your marketing team doesn't have a pipeline model. Your customer success function doesn't exist yet. Headcount growth needs to follow commercial architecture, not the other way around.

Expansion into new segments is stalling

Your first customers were early adopters in a specific niche. Now the board wants you in three new verticals and two new geographies. But each expansion requires different positioning, different regulatory considerations, and different sales motions. Neurotech expansion is not just 'do the same thing in a new market.' The clinical use cases, buyer personas, and reimbursement landscapes are fundamentally different across segments. Without a structured expansion framework, you'll spread too thin and lose momentum in your core market.

Your unit economics aren't clear enough to scale confidently

How much does it cost to acquire a neurotech customer? What's the lifetime value? How long until a new sales rep is productive? What's your net revenue retention? If you can't answer these questions precisely, you can't make informed decisions about where to invest. Many neurotech companies are growing without understanding their unit economics because the data is scattered across disconnected systems. You can't optimize what you can't measure.

How We Help

We begin with a commercial diagnostic that maps your current growth trajectory and identifies the specific bottlenecks preventing scale. This includes a deep analysis of your sales pipeline, win/loss patterns, customer acquisition costs, retention metrics, and team capacity. For neurotech companies, we also assess regulatory readiness for expansion and reimbursement coverage across target segments. The diagnostic tells us where the growth engine is breaking down and what to fix first.

From the diagnostic, we build a growth model that connects your commercial activities to revenue outcomes. This isn't a spreadsheet forecast — it's an operational model that shows how many leads you need, what conversion rates are realistic for your sales cycle, what marketing investment drives those leads, and how many sales reps you need at each revenue milestone. The model becomes your decision-making tool for budgeting, hiring, and strategy adjustments.

Revenue operations architecture is often the highest-impact workstream. Most neurotech companies have a CRM that's partially adopted, manual pipeline tracking, and no standardized sales process. We build the revenue operations infrastructure — CRM configuration, pipeline stages aligned to the neurotech buying process, lead scoring, handoff protocols, and reporting dashboards — that turns your sales function from art into science.

Expansion strategy defines where you grow next and how. We evaluate potential segments and geographies using a framework that weighs market size, competitive intensity, regulatory readiness, and distance from your current capabilities. Each expansion opportunity gets a business case with revenue projections, investment requirements, and risk assessment. For neurotech, this includes mapping FDA and international regulatory pathways for each new market.

Customer success and retention strategy is growth in disguise. Keeping a neurotech customer and expanding their usage is dramatically cheaper than acquiring a new one. We build the customer success function — onboarding playbooks, usage monitoring, expansion triggers, and renewal processes — that maximizes lifetime value. For device companies, this includes clinical support protocols and utilization tracking.

Team scaling strategy connects all of this to your hiring plan. We define the organizational design for your commercial function at each revenue milestone, specify the roles and seniority levels needed, and build the hiring sequence. This prevents the common mistake of hiring senior salespeople before you have the process and tools for them to succeed, or hiring junior people without the management layer to develop them.

The engagement produces a 12-month growth roadmap with quarterly OKRs, monthly milestones, and the operating cadences that keep everything on track. Growth strategy isn't a one-time document — it's a system that adapts as you learn from market feedback.

What we deliver

Commercial diagnostic — pipeline analysis, unit economics assessment, competitive positioning review, and growth bottleneck identification
Growth model — operational revenue model connecting marketing investment, sales capacity, and conversion rates to revenue targets
Revenue operations blueprint — CRM architecture, sales process design, pipeline management, and reporting infrastructure
12-month growth roadmap — expansion strategy, team scaling plan, quarterly OKRs, and budget allocation framework

Neurotech growth isn't about doing more — it's about building the commercial infrastructure that makes every dollar and every hire productive. The companies that scale are the ones that invest in their growth engine before they need it, not after their burn rate forces the conversation.

Our Methodology

The 90-day growth strategy sprint has three distinct phases. Days 1-30 are the commercial diagnostic and growth modeling phase. We analyze your current performance data, interview your team and customers, and build the growth model. The output is a clear picture of where you are, where the bottlenecks are, and what the math says about your growth potential. No assumptions — just data and market reality.

Days 31-60 are strategy development and infrastructure design. We build the revenue operations architecture, define the expansion framework, and develop the team scaling plan. Each strategy component is stress-tested against your budget constraints, regulatory timeline, and competitive dynamics. For neurotech companies, we also model scenario analysis around FDA milestones — what the growth plan looks like if clearance comes on time versus delayed.

Days 61-90 are implementation kickoff and operating rhythm establishment. We configure the systems, train the team, and launch the first set of growth initiatives. By day 90, you have a functioning growth engine with clear metrics, established cadences, and a team that knows exactly what they're doing and why. The roadmap extends 12 months, but the foundation is operational in 90 days.

How We Work

A growth strategy engagement involves a senior strategist, revenue operations specialist, and analyst. Your commitment is 4-6 hours per week from your CEO and commercial leadership during diagnostic, dropping to 2-3 hours during execution. We need access to your CRM, financial data, and customer contracts.

Cadence runs weekly strategy sessions in month one with working sessions for the RevOps build. Months two and three shift to bi-weekly strategy reviews and weekly implementation stand-ups. We present a formal 30/60/90 readout at each milestone.

We work as an extension of your team. Our strategist joins your pipeline reviews, our RevOps specialist works directly in your CRM, our analyst builds the dashboards your team will own. When the engagement ends, everything we've built belongs to you.

Expect hard conversations about resource allocation, market prioritization, and organizational design. Growth strategy often means saying no to opportunities that feel promising but don't fit. The discipline to focus is what separates companies that scale from companies that stay busy.

Predictable pipeline with clear conversion metrics and revenue forecasting capability
Structured expansion framework with prioritized segments and risk-adjusted growth targets
Operational commercial infrastructure that scales with the business and supports data-driven decision making

If your neurotech company needs growth strategy leadership, we should talk.

Expand your marketing team output with our experts

Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.

Frequently asked questions

How much does growth strategy cost for neurotech companies?

A full growth strategy engagement runs $125K-$250K for the 90-day sprint, including diagnostic, strategy development, and implementation kickoff. Ongoing advisory retainers for quarterly strategy refreshes run $15K-$25K per month. Compare that to the cost of a mis-hired VP of Sales ($200K+ in salary plus lost time) or a failed market expansion ($500K+ in wasted investment) and the math is straightforward.

How long before we see results from growth strategy?

You'll have an operational growth model and revenue operations infrastructure in 90 days. Pipeline improvements typically show within one to two quarters as the new sales process and marketing strategy take effect. Revenue impact follows your natural sales cycle — for neurotech enterprise deals, expect to see closed-revenue improvements 6-12 months after implementation. The growth model gives you leading indicators to track progress in the meantime.

How does the growth strategy team integrate with our existing staff?

We work alongside your commercial leadership and embed into your operating rhythms. If you have a VP of Sales or Marketing, we work with them as strategic partners. If those roles don't exist yet, we help define them and can serve as the interim strategic layer until you hire. Our revenue operations work happens directly in your systems, so there's no handoff gap when the engagement ends.

What makes Winston Francois different from a traditional growth strategy agency?

We build growth strategies for companies with regulatory constraints, long sales cycles, and technical buyers — not for SaaS companies optimizing a 14-day free trial. The growth playbook for neurotech is fundamentally different from standard B2B, and we know that from experience. We also stay through implementation rather than handing you a strategy deck. The strategy is only valuable if it's operational.

How do you measure ROI from a growth strategy engagement?

We define success metrics during the diagnostic phase based on your specific situation. Common metrics include pipeline velocity (deals moving faster through stages), conversion rate improvements, customer acquisition cost reduction, net revenue retention, and revenue per sales rep. We build the measurement infrastructure as part of the engagement so you're not guessing — you're tracking against clear baselines.

What type of neurotech company is the right fit for this service?

Post-product-market-fit neurotech companies between Series A and Series C are the ideal fit. You have customers, some revenue, and a mandate to grow — but the commercial function isn't keeping pace with the opportunity. If you're pre-revenue and still validating product-market fit, you need a go-to-market plan before a growth strategy. If you're at scale with a mature commercial team, you probably need targeted optimization rather than a full growth strategy buildout.